Literature DB >> 35438328

Computational study reveals substituted benzimidazole derivatives' binding selectivity to PI3Kδ and PI3Kγ.

Na-Na Zhang1, Xue Bai2, Shan-Shan Zhao1, Xue-Mei Zheng1, Lei Tang1, Sheng-Gang Yang3, Ji-Quan Zhang4.   

Abstract

Phosphatidylinositol 3-kinase (PI3K) is a key regulatory kinase in the PI3K/AKT/mTOR signaling pathway, which is involved in the regulation of cell proliferation, differentiation, apoptosis, and angiogenesis. Class IA PI3K isoforms γ and δ share a highly homologous ATP binding site and are distinguished by only a few residues around the binding site. Subtype-selective inhibitors have been proven to have great advantages in tumor treatment. Preliminary studies have obtained PI3K inhibitors bearing a benzimidazole structural motif with a certain selectivity for PI3Kδ and PI3Kγ subtypes. On this basis, we investigated the selective inhibitory mechanism of PI3Kδ and PI3Kγ using four developed inhibitors via molecular docking, molecular dynamics, binding free energy calculations, and residue energy decomposition. This study could provide references for the further development of PI3K-isoform-selective inhibitors.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Isoform selective inhibitors; MMGBSA; Molecular docking; Molecular dynamics; Phosphatidylinositol 3-kinase

Mesh:

Substances:

Year:  2022        PMID: 35438328     DOI: 10.1007/s00894-022-05096-w

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  2 in total

Review 1.  More than just kinases: the scaffolding function of PI3K.

Authors:  Carlotta Costa; Emilio Hirsch
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.